| ACIP | (CDC’s) Advisory Committee on Immunization Practice |
| ARDS | Acute respiratory distress syndrome |
| BCG | Bacillus Calmette–Guérin vaccine |
| CDC | Centers for Disease Control and Prevention |
| DIC | Disseminated intravascular coagulation |
| ECDC | European Centre for Disease Prevention and Control |
| EEA | European Economic Area |
| EU | European Union |
| HA | Hemagglutinin |
| HZ | Herpes zoster (shingles) |
| ICU | Intensive care unit |
| IPD | Invasive pneumococcal disease |
| MMR | Measles, mumps, rubella |
| MMRV | MMR with varicella |
| NA | Neuraminidase |
| PP | Pneumococcal pneumonia |
| PCVs | Pneumococcal conjugate vaccines |
| PPVs | Pneumococcal polysaccharide vaccines |
| PHN | Post-herpetic neuralgia |
| RBD | Receptor-binding domain |
| RSV | Respiratory syncytial virus |
| RSV-ARI | RSV-related acute respiratory illness |
| RSV-LRTD | RSV-related lower respiratory tract disease |
| RZV | Recombinant zoster vaccine |
| ZLV | Zoster live vaccine |
| VZV | Varicella zoster virus |
| WHO | World Health Organization |